Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
57.24
-0.38 (-0.66%)
Streaming Delayed Price
Updated: 12:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
234,996
Open
57.33
Bid (Size)
57.21 (1)
Ask (Size)
57.40 (4)
Prev. Close
57.62
Today's Range
57.23 - 58.46
52wk Range
31.52 - 58.26
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Performance
YTD
+18.83%
+18.83%
1 Month
+26.53%
+26.53%
3 Month
+45.50%
+45.50%
6 Month
+6.67%
+6.67%
1 Year
+56.05%
+56.05%
More News
Read More
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
Via
InvestorPlace
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
July 22, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
May 31, 2024
Via
Benzinga
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Via
Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
Via
InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
June 11, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
June 06, 2024
Via
Benzinga
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
May 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
May 22, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.